
1. antimicrob agents chemother. 2015 dec 28;60(3):1896-8. doi: 10.1128/aac.02302-15.

atovaquone-proguanil remains potential stopgap therapy multidrug-resistant 
plasmodium falciparum areas along thai-cambodian border.

saunders dl(1), chaorattanakawee s(2), gosi p(2), lanteri c(2), somethy s(3),
kuntawunginn w(2), ittiverakul m(2), chann s(4), gregory c(2), chuor cm(5), prom 
s(3), spring md(2), lon c(4).

author information: 
(1)u.s. army medical component-armed forces research institute medical
sciences (usamc-afrims), bangkok, thailand david.saunders.mil@afrims.org.
(2)u.s. army medical component-armed forces research institute medical
sciences (usamc-afrims), bangkok, thailand.
(3)royal cambodian armed forces, phnom penh, cambodia.
(4)usamc-afrims, phnom penh, cambodia.
(5)national center parasitology, entomology malaria control, phnom penh, 
cambodia.

our recent report dihydroartemisinin-piperaquine failure treat plasmodium
falciparum infections cambodia adds new urgency search alternative 
treatments. despite dihydroartemisinin-piperaquine failure, higher
piperaquine 50% inhibitory concentrations (ic50s) following reanalysis those
previously reported, p. falciparum remained sensitive atovaquone (atq) in
vitro. point mutations p. falciparum cytochrome b atq
resistance gene. mefloquine, artemisinin, chloroquine, quinine ic50s remained
comparable recent reports. atovaquone-proguanil may a
useful stopgap remains susceptible developing resistance used as
blood-stage therapy.

copyright Â© 2016, american society microbiology. rights reserved.

doi: 10.1128/aac.02302-15 
pmcid: pmc4775999
pmid: 26711753  [indexed medline]

